Dr. Reddy’s jumps as traders position ahead of May 12 FY26 earnings catalyst
RDY•Dr. Reddy’s (RDY) shares are higher as investors position ahead of the company’s FY26 results release and earnings call scheduled for May 12, 2026. A recent Form 6-K reiterated the timing, keeping attention on near-term catalysts after late-April regulatory momentum in Canada for generic semaglutide.
1. What’s moving the stock today
Dr. Reddy’s Laboratories’ American depositary shares (RDY) are trading higher in the latest session as the market looks ahead to the company’s upcoming quarterly and full-year FY26 results event. The company has scheduled its Q4 and full-year FY26 results release for Tuesday, May 12, 2026, followed by an earnings call at 10:00 a.m. ET, which is drawing incremental attention from event-driven buyers into the print.
2. The near-term catalyst investors are watching
The key near-term focal point is the May 12 results release and management commentary, with investors looking for updates on product momentum across regulated markets, margin trajectory, and any changes in growth outlook. A Form 6-K filed in late April reaffirmed the timing and distribution of results and the earnings call logistics, effectively putting a clear date on the next major information release for the ADR. ()
